Aker BioMarine Dirección

Dirección controles de criterios 3/4

El CEO de Aker BioMarine's es Matts Johansen , nombrado en Jul 2015, tiene una permanencia de 9.08 años. compensación anual total es $688.81K, compuesta por 61% salario y 39% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.25% de las acciones de la empresa, por valor de NOK105.23M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 3.4 años, respectivamente.

Información clave

Matts Johansen

Chief Executive Officer (CEO)

US$688.8k

Compensación total

Porcentaje del salario del CEO	61.0%
Permanencia del CEO	9.2yrs
Participación del CEO	1.2%
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Aug 20

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

Jul 19

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Jul 16

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Jul 11

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

Jun 03

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

Feb 15

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Nov 06

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Sep 06

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Nov 04

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Apr 13

Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 18

Loss-Making Aker BioMarine AS (OB:AKBM) Set To Breakeven

Jan 07

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Matts Johansen en comparación con los beneficios de Aker BioMarine?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$689k	US$420k	-US$9m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$300k
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$410k	US$401k	US$10m
Sep 30 2022	n/a	n/a	US$1m
Jun 30 2022	n/a	n/a	US$10m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$467k	US$459k	-US$8m
Sep 30 2021	n/a	n/a	US$3m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$630k	US$420k	-US$5m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$660k	US$450k	-US$24m

Compensación vs. Mercado: La compensación total ($USD688.81K) de Matts está en línea con el promedio de empresas de tamaño similar en el mercado Norwegian ($USD726.51K).

Compensación vs. Ingresos: La compensación de Matts ha aumentado mientras la empresa no es rentable.

CEO

Matts Johansen (48 yo)

9.2yrs

Permanencia

US$688,813

Compensación

Mr. Matts Johansen has been Chief Executive Officer at Aker BioMarine ASA since July 1, 2015. Mr. Johansen has been Chief Operating Officer of Aker Biomarine Antarctic AS since June 1, 2012. He serves as P...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Matts Johansen	Chief Executive Officer	9.2yrs	US$688.81k	1.25% $ 111.0m
Katrine Klaveness	Chief Financial Officer	6.7yrs	US$378.29k	sin datos
Hege Spaun	Chief Officer People & Communication	less than a year	US$221.24k	sin datos
Trond Smedsrud	Chief Executive Officer of Emerging Business	no data	US$284.93k	sin datos
Sigve Nordrum	Chief Commercial Officer of Feed Ingredients	no data	US$304.49k	sin datos
Tone Lorentzen	Chief Operating Officer of Human Health Ingredients	no data	US$339.88k	sin datos
Webjorn Barstad	Chief Executive Officer of Feed Ingredients	3.8yrs	US$515.11k	sin datos
Simon Seward	Chief Executive Officer of Human Health Ingredients	2.7yrs	US$306.31k	sin datos
Seth French	Chief Executive Officer of Lang Pharma Nutrition Inc	3yrs	US$834.94k	sin datos
Christopher Robin Vinter	Vice President of IR & Corporate Finance	no data	sin datos	sin datos
Lise Wiger	Financial Controller	no data	sin datos	sin datos

3.4yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AKBM se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kjell Røkke	Deputy Director	no data	sin datos	sin datos
Frank Reite	Director	no data	US$30.76k	sin datos
Anne Harris	Independent Director	3.5yrs	US$48.75k	sin datos
Ola Snøve	Chairman	10.7yrs	US$70.05k	0.98% $ 87.1m
Cilia Indahl	Director	3.5yrs	US$30.76k	sin datos
Sindre Skjong	Employee Representative Director	5.1yrs	sin datos	sin datos
Kimberly Mathisen	Director	2.4yrs	US$30.76k	sin datos
Kristin Holmgren	Employee Representative Director	1.3yrs	sin datos	0.0040% $ 351.2k
Thomas Rokke	Employee Representative Director	1.3yrs	sin datos	sin datos

3.5yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de AKBM se considera experimentada (3.3 años de antigüedad promedio).

Aker BioMarine Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

Chairman recently bought kr5.4m worth of stock

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

No independent directors

Recent updates

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2023)

Aker BioMarine AS Expects to Pay Extraordinary Dividend

Aker BioMarine AS Expects to Pay Extraordinary Dividend

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Aker BioMarine Antarctic Holding II AS completed the acquisition of Feed Ingredients business of Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.20 loss in 1Q 2023)

Consensus EPS estimates fall by 69%

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings released: US$0.10 loss per share (vs US$0.11 profit in FY 2022)

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.05 profit in 3Q 2022)

Aker BioMarine AS to Report Q1, 2024 Results on Apr 25, 2024

No independent directors

Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Consensus EPS estimates fall from profit to US$0.086 loss, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 308%

Consensus EPS estimates fall by 65%

Chairman recently bought kr5.4m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Consensus EPS estimates increase by 57%

Now 20% undervalued

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Consensus EPS estimates increase by 136%

Consensus forecasts updated

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

Now 20% undervalued

Forecast breakeven date moved forward to 2022

Now 22% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

Aker Biomarine AS Announces Board Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman recently bought kr9.4m worth of stock

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Chief Executive Officer recently bought kr3.3m worth of stock

Forecast breakeven pushed back to 2022

Forecast breakeven moved forward to 2021

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.08 loss in 1Q 2020)

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Aker BioMarine AS Announces Executive Elections

New 90-day low: kr106

Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2020 earnings released

Earnings beat expectations, revenue disappoints

Play Magnus Group and Aker Biomarine Signs A Four-Year Agreement for LYSOVETA